# Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

> **NCT02098538** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02098538
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-11-07
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-09-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02098538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02098538, "Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02098538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*